Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of Safety and Effectiveness of the TurboHawk and the SpiderFX for the Treatment of Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries in Japan

NCT02169921 is registered in ClinicalTrials.gov with Medtronic Endovascular as lead sponsor.

NCT NCT02169921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02169921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of Safety and Effectiveness of the TurboHawk and the SpiderFX for the Treatment of Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries in Japan
Lead sponsor
Medtronic Endovascular
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2014
Completion date
May 31, 2016
Enrollment
51 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral arterial disease